YD Bio Ltd is a biotechnology company specializing in the advancement of DNA methylation-based cancer detection technologies, as well as innovative therapies in regenerative medicine and ophthalmology. Its primary function is to develop and commercialize diagnostic tools and treatments that leverage proprietary and exclusively licensed technologies, aiming to address critical unmet needs in healthcare. Notably, YD Bio Ltd collaborates with biopharmaceutical partners to transform cutting-edge discoveries into clinically viable cancer diagnostics, such as blood-based early detection tests for pancreatic and breast cancer, currently accessible through laboratory-developed test platforms. In addition to its oncology portfolio, the company, in partnership with 3D Global Biotech, is advancing stem cell and exosome-based therapies for ocular diseases, including dry eye syndrome and corneal injuries, and plans to launch exosome-based treatments in clinical trials by 2027. YD Bio Ltd also supports global pharmaceutical research through the supply of investigational drugs and ancillary materials for clinical trials. Founded in 2013 and led by an experienced biomedical management team, YD Bio Ltd plays a strategic role in driving innovation and expanding access to advanced healthcare solutions within the biotech sector.